Key result
Olmesartan prevented isoproterenol-induced left ventricular hypertrophy across all groups, but only improved diastolic function and pulmonary congestion in sham-operated males and ovariectomized females.
Why the study?
Although HFpEF is more common in postmenopausal women than in men, the effect of sex hormones on cardiac diastolic function remains unclear.
Does olmesartan improve cardiac hypertrophy and diastolic dysfunction in an isoproterenol-induced mouse model of HFpEF across different sex hormone statuses?
Does olmesartan improve cardiac hypertrophy and diastolic dysfunction in an isoproterenol-induced mouse model of HFpEF across different sex hormone statuses?
In a mouse model of HFpEF, olmesartan improved diastolic dysfunction and pulmonary congestion more effectively in male and ovariectomized female mice, suggesting sex hormones modulate the therapeutic potential of ARBs.
Answers are grounded in this paper and cite their sources.
Olmesartan effects on diastolic function may be sex- and hormone-dependent in this model; leaves open translation to human HFpEF.
BACKGROUND: Although heart failure (HF) with preserved ejection fraction (HFpEF) is more common in postmenopausal women than in men, the effect of sex hormones on cardiac diastolic function remains unclear. We examined the effect of gonadectomy with or without the angiotensin receptor blocker olmesartan (Olm) in an isoproterenol (ISO) -induced mouse model of left ventricular hypertrophy (LVH) and cardiac diastolic dysfunction. METHODS: ISO or ISO with Olm were administered for 28 days in sham-operated male and female, castrated (CAS), and ovariectomized (OVX) mice. LV ejection fraction (EF) and E/A ratio were analyzed by echocardiography, and the LV and lung weight corrected by tibial length were used as indices of LVH and lung congestion, respectively. RESULTS: On echocardiography, systolic function did not differ between the four groups. LV/tibial length (TL) and Lung/TL significantly increased in all groups. The LV/TL ratio was lower in castrated-ISO vs. Male-Sham-ISO but did not differ between Female-Sham-ISO and OVX-ISO. However, the Lung/TL ratio of OVX-ISO was greater than that of Female-Sham-ISO. Olm prevented LV hypertrophy in all groups. The decrease in E/A and increase in lung weight were improved by Olm in Male-Sham and OVX-ISO but not in the other groups. CONCLUSION: These sex differences suggest that sex hormones play a pivotal role in modulating cardiac hypertrophy and diastolic dysfunction induced by chronic β-adrenoceptor stimulation, and thus affect the therapeutic potential of angiotensin receptor blockade.
No takes yet. Share an insight, caveat, or question.
Asai et al. (2020) studied Isoproterenol-induced cardiac diastolic dysfunction (HFpEF model) (n=132). Olmesartan vs. Vehicle (no olmesartan) was evaluated on Left ventricular weight to tibial length ratio (LVW/TL) and E/A ratio (p=<0.05). Olmesartan prevented isoproterenol-induced left ventricular hypertrophy across all groups, but only improved diastolic function and pulmonary congestion in sham-operated males and ovariectomized females.
Synapse has enriched 10 related papers. Consider them for comparative context: